A detection model for cognitive dysfunction based on volatile organic compounds from a large Chinese community cohort

INTRODUCTION We explored whether volatile organic compound (VOC) detection can serve as a screening tool to distinguish cognitive dysfunction (CD) from cognitively normal (CN) individuals. METHODS The cognitive function of 1467 participants was assessed and their VOCs were detected. Six machine learning algorithms were conducted and the performance was determined. The plasma neurofilament light chain (NfL) was measured. RESULTS Distinguished VOC patterns existed between CD and CN groups. The CD detection model showed good accuracy with an area under the receiver-operating characteristic curve (AUC) of 0.876. In addition, we found that 10 VOC ions showed significant differences between CD and CN individuals (p < 0.05); three VOCs were significantly related to plasma NfL (p < 0.005). Moreover, a combination of VOCs with NfL showed the best discriminating power (AUC = 0.877). DISCUSSION Detection of VOCs from exhaled breath samples has the potential to provide a novel solution for the dilemma of CD screening.

[1]  L. Sambati,et al.  Diagnostic value of plasma p-tau181, NfL, and GFAP in a clinical setting cohort of prevalent neurodegenerative dementias , 2022, Alzheimer's Research & Therapy.

[2]  Ting Huang,et al.  A feasibility study of Covid-19 detection using breath analysis by high-pressure photon ionization time-of-flight mass spectrometry , 2022, Journal of breath research.

[3]  P. Yadav,et al.  Redefining oxidative stress in Alzheimer's disease: Targeting platelet reactive oxygen species for novel therapeutic options. , 2022, Life sciences.

[4]  J. Cryan,et al.  Microbial-derived metabolites as a risk factor of age-related cognitive decline and dementia , 2022, Molecular neurodegeneration.

[5]  Jonathan J. Evans,et al.  Examination of the validity of the ‘Papadum test’: An alternative to the clock drawing test for people with low levels of education , 2022, The Clinical neuropsychologist.

[6]  A. Flügel,et al.  The lung microbiome regulates brain autoimmunity , 2022, Nature.

[7]  Marina F Englesakis,et al.  Rapid cognitive assessment tools for screening of mild cognitive impairment in the preoperative setting: A systematic review and meta-analysis. , 2022, Journal of clinical anesthesia.

[8]  M. Uddin,et al.  Current understandings and perspectives of petroleum hydrocarbons in Alzheimer’s disease and Parkinson’s disease: a global concern , 2022, Environmental Science and Pollution Research.

[9]  Min Zhu,et al.  A metabolite panel that differentiates Alzheimer's disease from other dementia types , 2021, Alzheimer's & dementia : the journal of the Alzheimer's Association.

[10]  M. Bondi,et al.  Elevated plasma neurofilament light predicts a faster rate of cognitive decline over 5 years in participants with objectively‐defined subtle cognitive decline and MCI , 2021, Alzheimer's & dementia : the journal of the Alzheimer's Association.

[11]  M. Qiu,et al.  Assessment of an Exhaled Breath Test Using High-Pressure Photon Ionization Time-of-Flight Mass Spectrometry to Detect Lung Cancer , 2021, JAMA network open.

[12]  R. Trullas,et al.  Cholesterol alters mitophagy by impairing optineurin recruitment and lysosomal clearance in Alzheimer’s disease , 2020, Molecular Neurodegeneration.

[13]  N. Kandiah,et al.  Development and validation of a brief visual based cognitive screening tool for dementia: the Visual Cognitive Assessment Test short-form (VCAT-S) , 2020, Journal of Neurology Neurosurgery & Psychiatry.

[14]  Bo-Han Su,et al.  Human Breathomics Database , 2020, Database J. Biol. Databases Curation.

[15]  D. Harvey,et al.  Plasma biomarkers of astrocytic and neuronal dysfunction in early- and late-onset Alzheimer's disease , 2019, Alzheimer's & Dementia.

[16]  E. Ifeachor,et al.  Breath-based non-invasive diagnosis of Alzheimer’s disease: a pilot study , 2019, Journal of breath research.

[17]  J. Jia,et al.  Concordance between the assessment of Aβ42, T-tau, and P-T181-tau in peripheral blood neuronal-derived exosomes and cerebrospinal fluid , 2019, Alzheimer's & Dementia.

[18]  Aaron O'Leary,et al.  PyWavelets: A Python package for wavelet analysis , 2019, J. Open Source Softw..

[19]  Ludwig Kappos,et al.  Neurofilaments as biomarkers in neurological disorders , 2018, Nature Reviews Neurology.

[20]  R. Snell,et al.  Emergence of breath testing as a new non-invasive diagnostic modality for neurodegenerative diseases , 2018, Brain Research.

[21]  C. Rowe,et al.  High performance plasma amyloid-β biomarkers for Alzheimer’s disease , 2018, Nature.

[22]  Joon-Boo Yu,et al.  Investigation of Exhaled Breath Samples from Patients with Alzheimer’s Disease Using Gas Chromatography-Mass Spectrometry and an Exhaled Breath Sensor System , 2017, Sensors.

[23]  H. Haick,et al.  Diagnosis and Classification of 17 Diseases from 1404 Subjects via Pattern Analysis of Exhaled Molecules , 2016, ACS nano.

[24]  F. Jessen,et al.  Measuring Compounds in Exhaled Air to Detect Alzheimer's Disease and Parkinson’s Disease , 2015, PloS one.

[25]  A. Mazzatenta,et al.  Volatile organic compounds (VOCs) fingerprint of Alzheimer's disease , 2015, Respiratory Physiology & Neurobiology.

[26]  J. Jia,et al.  The prevalence of dementia in urban and rural areas of China , 2014, Alzheimer's & Dementia.

[27]  L. Schöls,et al.  Hepatic mitochondrial dysfunction in Friedreich Ataxia , 2011, BMC neurology.

[28]  A. Copani,et al.  Alzheimer's disease: brain expression of a metabolic disorder? , 2010, Trends in Endocrinology & Metabolism.

[29]  H. Haick,et al.  Detection of lung, breast, colorectal, and prostate cancers from exhaled breath using a single array of nanosensors , 2010, British Journal of Cancer.

[30]  L. Koski,et al.  French-English Cross-Linguistic Comparison and Diagnostic Impact of the AD-8 Dementia Screening Questionnaire in a Geriatric Assessment Clinic , 2010, Dementia and Geriatric Cognitive Disorders.

[31]  E. Golovinsky,et al.  Inhibitory Effect of Some Acetyl Esters and Acetamides on Glycation of the Histone H1 , 2008, Zeitschrift fur Naturforschung. C, Journal of biosciences.

[32]  J P Miller,et al.  The AD8 , 2005, Neurology.

[33]  M. Boada,et al.  Human plasma semicarbazide sensitive amine oxidase (SSAO), β-amyloid protein and aging , 2005, Neuroscience Letters.

[34]  J. Woodward,et al.  Inhibition of neuronal nicotinic acetylcholine receptors by the abused solvent, toluene , 2002, British journal of pharmacology.

[35]  R. Martins,et al.  Intraneuronal advanced glycation endproducts in presenilin‐1 Alzheimer's disease , 2002, Neuroreport.

[36]  C. Bell.  DSM-IV: Diagnostic and Statistical Manual of Mental Disorders , 1994 .

[37]  H. Haick,et al.  Detection of Alzheimer's and Parkinson's disease from exhaled breath using nanomaterial-based sensors. , 2013, Nanomedicine.

[38]  T. O'donohue,et al.  Ethoxyethanol behavioral teratology in rats. , 1981, Neurotoxicology.